Effects of an Exclusive Human Milk Diet on Early Vascular Aging Risk in Extremely Preterm and Term Children
Led by Prolacta Bioscience · Updated on 2025-08-29
200
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research aims to understand how early life nutrition affects long-term cardiovascular health in extremely preterm infants. It focuses on the origins of early vascular aging, which starts in fetal and neonatal life and contributes to risks like obesity, high blood pressure, and abnormal metabolism. The study compares the effects of an exclusive human milk diet on these health risks in very premature babies. The trial also includes a control group of full-term children for comparison.
The trial randomly assigns extremely preterm infants to one of two feeding groups one receiving an exclusive human milk diet with a human milk fortifier until 36 weeks of gestation, and the other receiving human milk with fortifier until 32 weeks, then switching to human milk with a bovine-based fortifier or preterm formula. After 36 weeks, both groups receive human milk with bovine fortifier or preterm formula. The control group consists of term-born children matched by age, recruited at five years from kindergartens, with birth data collected from clinical records.
Participants in the preterm groups are followed with visits at one, two, and five years of age, while term controls provide data at five years. The study evaluates fasting blood glucose, blood pressure, and aortic distensibility from birth to five years as primary outcomes. Secondary outcomes include body mass index, insulin sensitivity, and lipid profiles. The total study duration is planned for 96 months with a recruitment phase lasting 36 months.
CONDITIONS
Brief Title
Exclusive Human-milk in Preterm NEOnates and Early VASCular Aging Risk Factors (NEOVASC)
Research Team
U
Ursula Kiechl-Kohlendorfer, MD, MSc
W
Wolfgang Mitterer, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Extremely preterm infants with a birth weight of 500-1250g
Feeding is NPO or exclusive human milk prior to enrollment
Parent(s) willing to sign informed consent
Term-born children with an adequate birth weight
Parent(s) willing to sign informed consent
You will not qualify if you...
Infants with a birth weight less than 500g or greater than 1250g
Diagnosed with inborn errors of metabolism such as galactosemia or phenylketonuria
Not fed exclusive human milk diet prior to enrollment
Presence of major congenital malformation
Presence of intestinal perforation or Stage 2 Necrotizing enterocolitis prior to enrollment
Parent(s) not willing to sign informed consent
Unable to participate due to medical reasons or unlikely survival
Term-born subjects with acute or chronic illness
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - From birth until 36 weeks of gestation
Participants receive an exclusive human milk diet with human milk fortifiers until 36 weeks of gestation or a mixed diet with human milk and fortifiers until 32 weeks followed by bovine-based fortifiers or preterm formula until 36 weeks of gestation.
Visits during the neonatal period as per clinical care
Follow-up
Duration - Up to 5 years of age
Participants attend follow-up visits to assess metabolic and vascular health outcomes at one, two, and five years of age.
3 visits (at 1, 2, and 5 years of age)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Comparing Ampicillin With and Without Azithromycin for Women With Late Preterm Premature Rupture of Membranes Between 34 and 36.6 Weeks
Study of Caffeine Citrate Treatment in Late Preterm Infants With Respiratory Distress to Reduce Respiratory Support Duration
Testing the Calmer Therapy Bed to Support Growth and Brain Development in Preterm Infants Born at 26 to 30 Weeks in the NICU
Darbepoetin Plus Slow-Release Intravenous Iron to Reduce Blood Transfusions and Support Iron Levels and Brain Development in Preterm Infants Born Before 32 Weeks
Impact of Different Intervention Approaches on Neuropsychomotor Development in Premature Babies Using the ICF Biopsychosocial Model
Study of Early Crawling Training Using a Mini-Skateboard to Help Motor Development in Very Premature Infants at Risk for Developmental Delays
Study of Wearable Wireless Sensors to Continuously Monitor Vital Signs in ICU and Pediatric Patients Under 18
Effects of an Exclusive Human Milk Diet on Early Vascular Aging Risk in Extremely Preterm and Term Children
Study of Low Versus High Flow Rates in High Flow Nasal Ventilation and Their Effect on Carbon Dioxide Levels in Preterm Infants
Study of Maternal Stress, Breast Milk Composition, and Neurodevelopment in Preterm Infants Born Between 28 and 34 Weeks
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effects of an exclusive human-milk diet in preterm neonates on early vascular aging risk factors (NEOVASC): study protocol for a multicentric, prospective, randomized, controlled, open, and parallel group clinical trial.
Wolfgang Mitterer, Christoph Binder, Anya Blassnig-Ezeh...